Lipocine (LPCN) Stock Price, News & Analysis

Company Overview

Lipocine Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S. Food and Drug Administration for the treatment of male hypogonadism. In parallel, Lipocine is advancing LPCN 1144, an oral formulation of testosterone undecanoate, for the treatment of nonalcoholic steatohepatitis (NASH) and related metabolic disorders. Ongoing clinical studies seek to confirm the safety and efficacy of these candidates while exploring additional indications that may benefit from Lipocine’s delivery platforms.

Headquartered in Salt Lake City, Utah, Lipocine serves a global market, conducting operations and clinical trials primarily in the United States but also engaging with partners and regulators in Europe and Asia. The organization maintains research collaborations and licensing discussions to extend the reach of its technologies and to explore new therapeutic areas. Its facilities support formulation development, analytical testing, and scale-up processes needed to transition products from the laboratory to commercial manufacture.

Since its founding in 1996, Lipocine has been led by Chief Executive Officer William D. Kaan, who has guided the company through pivotal clinical milestones and regulatory submissions. Under his leadership, Lipocine continues to pursue a strategic path toward product approvals, commercialization partnerships, and the expansion of its lipid-based delivery platforms. The company’s management team comprises experienced professionals in pharmaceutical development, regulatory affairs, and corporate strategy, all dedicated to delivering innovative therapies that improve patient outcomes.

Key Stats

• Today's Range: $2.19 to $2.30
• 50-Day Range: $1.94 to $9.25
• 52-Week Range: $1.81 to $12.37
• Volume: 81,695 shs
• Average Volume: 298,207 shs
• Market Capitalization: $18.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Lipocine Stock Analysis - MarketRank™

Lipocine scored higher than 80% of companies evaluated by MarketBeat, and ranked 146th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Lipocine has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Lipocine has a consensus price target of $15.00, representing about 566.7% upside from its current price of $2.25.

Amount of Analyst Coverage

Lipocine has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipocine is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipocine is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipocine has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.32% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 0.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently decreased by 41.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipocine does not currently pay a dividend.

Dividend Growth

Lipocine does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.51

News Sentiment

Lipocine has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lipocine this week, compared to 2 articles on an average week.

Search Interest

Only 11 people have searched for LPCN on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Lipocine in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $434,600.00 in company stock, which represents 2.3441% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $434,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

6.35% of the stock of Lipocine is held by insiders.

Percentage Held by Institutions

9.11% of the stock of Lipocine is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/29/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPCN
• CIK: 1535955
• Web: www.lipocine.com
• Phone: (801) 994-7383
• Fax: 801-994-7388
• Employees: 10
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Lipocine: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +566.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.63 million
• Net Margins: -571.18%
• Pretax Margin: -571.13%
• Return on Equity: -66.70%
• Return on Assets: -59.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.99
• Quick Ratio: 9.99

Sales & Book Value

• Annual Sales: $1.98 million
• Price / Sales: 9.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.77 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 8,240,000
• Free Float: 7,721,000
• Market Cap: $18.54 million
• Optionable: No Data
• Beta: 0.50